Back HCV Treatment

HCV Treatment

AASLD 2015: High Cure Rate for People Retreated After Failure of Short Course DAA Therapy

Hepatitis C patients who did not achieve sustained virological response with a prior short course of direct-acting antiviral (DAA) therapy had a high likelihood of being cured if treated again with sofosbuvir/ledipasvir standard therapy, according to results from the SYNERGY study presented at the 2015 AASLD Liver Meeting last week in San Francisco. A related analysis showed that emergence of certain drug-resistance mutations was common during very short therapy, but this did not appear to compromise response to retreatment.

alt

Read more:

AASLD 2015: HCV Triple Regimen Cures Rapid Responders in 3 Weeks

Response-guided therapy using an all-oral regimen of 3 direct-acting antivirals cured a majority of easier-to-treat genotype 1b hepatitis C patients in just 3 weeks, according to results from the small SODAPI pilot study, presented in a late-breaking poster at the AASLD Liver Meeting last week in San Francisco. Further research will be needed to see if these promising results hold for larger patient populations.

alt

Read more:

Coverage of the 2015 AASLD Liver Meeting

HIVandHepatitis.com coverage of the 2015 American Association for the Study of Liver Diseases (AASLD) Liver Meeting in San Francisco, November 13-17, 2015.

Conference highlights include interferon-free therapy for hepatitis C, treatment for difficult-to-treat populations including people with HCV genotype 3 and liver  cirrhosis, hepatitis B prevention and treatment, and management of advanced liver disease.

Full listing by topic

Liver Meeting website

11/23/15

alt

AASLD 2015: Study Reveals Potential Challenges for Scaling Up Hepatitis C Therapy in the UK

A large proportion of people with chronic hepatitis C virus (HCV) infection in the UK have comorbidities, hazardous use of drugs and alcohol, and are taking medications that could potentially interact with HCV direct-acting antivirals (DAAs), according to research presented at the 2015 AASLD Liver Meeting in San Francisco. The investigators caution that clinicians "need to be aware" of the potential for interactions when choosing HCV treatment regimens.

alt

Read more:

AASLD 2015: Daclatasvir + Sofosbuvir with Ribavirin Cures 90% of Genotype 3 Hepatitis C Patients

An all-oral combination of daclatasvir, sofosbuvir, and ribavirin taken for 12 or 16 weeks led to high sustained virological response rates for people with hard-to-treat hepatitis C virus (HCV) genotype 3 and advanced liver fibrosis or cirrhosis, according to findings from the ALLY-3+ study presented at the 2015 AASLD Liver Meeting this week in San Francisco.

alt

Read more: